Promotion of Flector Tissugel 140mg medicated plaster (diclofenac epolamine) by Windzor Pharma Ltd
Published 14 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-august-2021/promotion-of-flector-tissugel-140mg-medicated-plaster-diclofenac-epolamine-by-windzor-pharma-ltd
A healthcare professional complained about an email promoting Flector, sent by Windzor Pharma Ltd. to healthcare professionals in February 2020. The complainant alleged that the email and attached material provided misleading information about the indication and discussed off licence use of the product.
MHRA did not uphold the complaint on the specific issue of off-label promotion. Advice was provided to Windzor Pharma to ensure that appropriate comparators are chosen in future to promote rational use of the products.